Center for Drug Evaluation and Research (CDER)

### Antiviral Drugs Advisory Committee (AVDAC) Meeting

FDA White Oak Campus, Building 31, The Great Room (Rm. 1503) White Oak Conference Center, Silver Spring, Maryland May 10, 2012

#### DRAFT MEETING ROSTER

#### **ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)**

#### Yvette Waples, Pharm.D.

Division of Advisory Committee and Consultant Management Office of Executive Programs, CDER, FDA

## ANTIVIRAL DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

#### Amanda H. Corbett, Pharm.D.

Clinical Assistant Professor University of North Carolina Eshelman School of Pharmacy Division of Pharmacotherapy and Experimental Therapeutics Chapel Hill, North Carolina

### Demetre C. Daskalakis, M.D., M.P.H.

Assistant Professor New York University School of Medicine Infectious Diseases and Immunology Division New York, New York

### Susan S. Ellenberg, Ph.D.

Professor of Biostatistics
Associate Dean for Clinical Research
University of Pennsylvania School of Medicine
Center for Clinical Epidemiology and Biostatistics
Philadelphia, Pennsylvania

### Thomas P. Giordano, M.D., M.P.H.

Assistant Professor of Medicine
Baylor College of Medicine
Medical Director of HIV Services
Harris County Hospital District
HSR&D Center of Excellence
Michael E. DeBakey VA Medical Center
Houston, Texas

### Jeffrey S. Glenn, M.D., Ph.D.

Associate Professor of Medicine Division of Gastroenterology and Hepatology Director, Center for Hepatitis and Liver Tissue Engineering Stanford University School of Medicine Stanford, California

# Yoshihiko Murata, M.D., Ph.D.

Assistant Professor of Medicine
Division of Infectious Diseases
University of Rochester School of Medicine and
Dentistry
Rochester, New York

### **Daniel Raymond**

(Consumer Representative)
Policy Director
Harm Reduction Coalition
New York, New York

#### Doris B. Strader, M.D.

Associate Professor of Medicine Fletcher Allen Health Care The University of Vermont College of Medicine Division of Gastroenterology Burlington, Vermont

Center for Drug Evaluation and Research (CDER)

### Antiviral Drugs Advisory Committee (AVDAC) Meeting

FDA White Oak Campus, Building 31, The Great Room (Rm. 1503) White Oak Conference Center, Silver Spring, Maryland May 10, 2012

### **DRAFT MEETING ROSTER (cont.)**

### ANTIVIRAL DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

#### Russell B. Van Dyke, M.D.

Professor of Clinical Pediatrics Head, Section of Pediatric Infectious Diseases Tulane University School of Medicine New Orleans, Louisiana

#### **TEMPORARY MEMBERS (Voting)**

#### Sally Blower, Ph.D.

Director of Center for Biomedical Modeling Semel Institute for Neuroscience & Human Behavior UCLA David Geffen School of Medicine Los Angeles, California

#### Laura W. Cheever, M.D., ScM

Deputy Associate Administrator and Chief Medical Officer, HIV/AIDS Bureau
Health Resources and Services Administration
Department of Health and Human Services
Rockville, Maryland

### Michelle M. Estrella, M.D., M.H.S

Assistant Professor and Associate Fellowship Program Director, Nephrology Division Johns Hopkins University School of Medicine Baltimore, Maryland

# Judith Feinberg, M.D., FACP, FIDSA

(Acting Chairperson)

Associate Chair of Medicine for Faculty
Development
University of Cincinnati College of Medicine
Division of Infectious Diseases
Holmes Hospital
Cincinnati, Ohio

# Lawrence G. Hunsicker, M.D.

Professor of Medicine Emeritus Medical Director of Organ Transplantation, Nephrology Division University of Iowa College of Medicine Iowa City, Iowa

#### David T. Kuhar, M.D.

Medical Officer, Prevention and Response Branch Division of Healthcare Quality Promotion Centers for Disease Control and Prevention (CDC) Atlanta, Georgia

## Elaine H. Morrato, Dr.PH., M.P.H., C.P.H.

Assistant Professor
Departments of Health Systems, Management &
Policy Clinical Pharmacy and Pediatrics
Assistant Director
Children's Outcomes Research Program
Anschutz Medical Campus
University of Colorado-Denver
Aurora, Colorado

#### Susan Newcomer, Ph.D.

Statistician/Demographer Demographic and Behavioral Sciences Branch Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health (NIH) Bethesda, Maryland

Center for Drug Evaluation and Research (CDER)

### Antiviral Drugs Advisory Committee (AVDAC) Meeting

FDA White Oak Campus, Building 31, The Great Room (Rm. 1503) White Oak Conference Center, Silver Spring, Maryland May 10, 2012

## **DRAFT MEETING ROSTER (cont.)**

### **TEMPORARY MEMBERS (Voting)**

#### Nancy S. Padian, Ph.D., M.P.H.

Adjunct Professor of Epidemiology University of California, Berkeley School of Public Health Berkeley, California

## Monica S. Ruiz, Ph.D., M.P.H.

Visiting Assistant Professor George Washington University School of Public Health and Health Services Department of Prevention and Community Health Washington, District of Columbia

# (Patient Representative) New York, New York

Marlena Vega, MSW, Ph.D.

### Lauren V. Wood, M.D.

Captain, United States Public Health Service Health Disparities Specialist Senior Clinical Investigator, Vaccine Branch National Cancer Institute (NCI), NIH Bethesda, Maryland

### Matthew V. Sharp

(Patient Representative)
San Francisco, California

#### ACTING INDUSTRY REPRESENTATIVE TO THE COMMITTEE (Non-Voting)

#### Patrick A. Robinson, M.D.

(Acting Industry Representative)
Executive Director and Deputy

International Therapeutic Area Head-Virology Boehringer Ingelheim Pharmaceuticals, Inc.

Ridgefield, Connecticut

### **GUEST SPEAKER (Non-Voting)**

#### Susan Buchbinder, M.D.

Director, HIV Research Section San Francisco Department of Public Health San Francisco, California

### **CDC SPEAKER (Non-Voting)**

### Lynn A. Paxton, M.D., M.P.H.

Captain, United States Public Health Service Medical Epidemiologist, Epidemiology Branch Division of HIV/AIDS Prevention, CDC Atlanta, Georgia

Center for Drug Evaluation and Research (CDER)

# Antiviral Drugs Advisory Committee (AVDAC) Meeting

FDA White Oak Campus, Building 31, The Great Room (Rm. 1503) White Oak Conference Center, Silver Spring, Maryland May 10, 2012

## **DRAFT MEETING ROSTER (cont.)**

### **NIH SPEAKER (Non-Voting)**

### Jeanna M. Piper, M.D.

Senior Medical Officer, Division of AIDS National Institute of Allergy and Infectious Diseases, NIH Bethesda, Maryland

# FDA PARTICIPANTS (Non-Voting)

### Edward Cox, M.D., M.P.H.

Director Office of Antimicrobial Products (OAP) OND, CDER, FDA

#### Jeffrey Murray, M.D., M.P.H.

Deputy Director DAVP, OAP, OND, CDER, FDA

# Peter Miele, M.D.

Medical Officer DAVP, OAP, OND, CDER, FDA

## Debra B. Birnkrant, M.D.

Director Division of Antiviral Products (DAVP) OAP, OND, CDER, FDA

#### Kendall A. Marcus, M.D.

Deputy Director for Safety DAVP, OAP, OND, CDER, FDA